COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA

Abstract: The present invention is related to a pharmaceutical composition suitable for the treatment of schizophrenia comprising an acid addition salt of (1)-N-(1-phenylisopropyl)-N-methyl-propynyl-amine in a therapeutically effective amount and optionally one or more neuroleptica and pharmaceutically acceptable carriers, and other excipients.

Description: COMPOSITION FOR THE TREATMENT OF SCHISOPHRENIA The present invention relates to the treatment of schisophrenia characterized by negative symptoms by selegiline (1-Deprenyl) (-)-N-(l-phenylisopropyD-N- -methyl-propynylamine and to a composition for this treatment . About one third of the schisophreπic patients amounting to 1% of the total population is characterized by negative symptoms, i.e. said patients suffer from schisophrenia of type II. according to Crow. , i.e. they loose interest about themselves and their environment, their cognitive function gets damaged and their orientation to the future is characterized by ambivalence and ambi- tendency. The conventional neuroleptica as such are not successful, on the other hand, they may be harmful due to their side effects. (Ideggyόgyaszati Szemle 1983, Psych. Res. 1984.) Several compounds were tested for the treatment of these patients in order to find an effective drug and in order to be able to send home the patients treated for a long time in mental social homes. Morphological changes are supposed to be observed in schisophrenic patients characterized by negative symptoms. (Brit. 3 . Psych. 1980, Brit. Med. 3 . 1983. Psychopharmacology Basic Aspects 1980, Schizophr. Bull. 1982, Arch. Gen. Psych. 1982, Arch. Gen. Psych. 1982, Arch. Gen. Psych. 1986.) It is known that within the nerve system the dopamine hypofunction is in connection with the Parkinson disease (Klin. schr. 1960. ) leading to the treatment with 1-DOPA (Canad. med. Ass. 3. 1969.). But the increase of the dopaminerg tone concerning the whole organism, was accompanied by several side effects (hypertonic crisis, tremor, gastrointestinal disorders etc.). It is further known that 1-deprenyl inhibits ' the monoamino-oxydase-B (MAO-B) enzyme, i.e. it acts as dopa ine agonist (Arch. Intern. Pharmacodyn. 1965.). Schisophrenia is characterized according to our present knowledge by the hyperactivity of the mesocortical system, which can be located mainly to the nucleus accumbens. This hyperactivity is decreased by neuroleptica. Post-mortem investigations have proved that the number of dopamine receptors of the above brain parts increases upon long neuroleptic treatment. (A pszichiatria alapjai, Akademia Kiadό Budapest 1986. p. 168.). On the basis of this knowledge it could not be expected that selegiline is suitable for the treatment of schisophrenia. The psychiatric indications of the successfully tested selegiline are given on the basis of the New Haven Schisophrenia index, the Carpenter-Strauss-Bartko WHO Flexible System and the DSM III systems. In each case the precondition is the confirmation of the diagnosis of the schisophrenia and the exclusion of organic, toxic (drug, alcohol), affective pathological forms. Considering these results the selegiline is suggested for the following symptoms: slow and almost symptomless beginning, deficiency in impulses, introversion, lack of rapport ability, hesitating speech, poor associa¬ tions, insensibility, asthenia, lack of feeling of joy, instinct dynamical fading, poor social and working connec¬ tions, isolation. The group of symptoms can ' appear at the beginning of the pathological process of schisophrenia ^ or at its subchronic or chronic period as well. Selegiline is applied at a daily dosage of 10-50 mg on each occasion at 5-10 mg, preferably orally or intra¬ muscularly. It may be administered together with one or more neuroleptica. It is suggested to carry on with the treatment for at least one month, but depending on the condition of the patient the treatment may be prolonged for a longer period. The used selegiline can be prepared by methods disclosed in HU PS 154 655 and 187 775. The most preferred drug forms are the tablets and capsules. Neuroleptica are a group of compounds defined in the Dictionary of Pharmacology (Blackwell Scientific. Publ. Oxford 1985, p. 143), the best known representatives of this group are chlorpromazine, thioridazine, flufen- azine, haloperidol and pimozide. The maintaining neuro¬ leptic treatment is carried out with the usual therapeutic doses. The pharmaceutical compositions according to the invention are prepared by using selegiline and optional¬ ly the known neuroleptica by methods known per se. Example 1 In an open test 13 chronic schisophrenic patients were administered selegiline for 6 weeks, and this was followed by a 5 weeks tapering-off period. The dosage was 15 mg/day. The patients were characterized by the chronicity and by the negative symptoms, by the lack of positive symptoms, they were selected on the basis of these symptoms. The changes of the psychic condition were followed by the following methods: Brief Psychiatric Rating Scale (Overall and Gorham 1962.), Nurses Observation Scale for Inpatient Evaluation (Guy, . : ECDEU Assessment Manual for Psychopharmacology . Department of Health Education and Welfare Publication No. 76-338. Superintendent of Documents US Government Printing Office, Washington DC, 1976 p.: 266-273) and Negative Symptom Rating Scale Oager et al. , 1985.). The changes of the possible extrapyramidal symptoms as well as their formation or their ceasing were followed by Abnormal Involuntary Movement Scale see: the Nurses Observation Scale from page 534, and Targeting Abnormal Kinetic Effect (Wojcik et al., 1980, Comprehensive Psychiatry, 21. p. 370). During the examination none of the patients dropped out. On the Negative Symptom Rating Scale a significant improvement could be observed already after the first week of treatment and this significant improve¬ ment could be shown to the end of the treatment until the period after the tapering-off . The patients were treated during the whole examination with the unchanged neuroleptica. The rating was carried out on the 0., 10. , 24., 44. day and then after another 5 weeks. Example 2 Preparation of 150 mg tablets 50 g of selegiline-hydrochloride , 30 g of talc, 30 g of magnesium stearate, 90 g of polyvidone, 460 g of starch, 840 g of lactose were admixed by methods known per se, followed by granulation and the mixture was compressed to 150 mg tablets. About 10 000 tablets containing 5 mg selegiline-hydrochloride were prepared.

Claims: C l a i m s 1. Pharmaceutical composition suitable for the treatment of schisophrenia c omp r i s i n g an acid addition salt of (D-N-(l-phenyl-isopropyl)-N-methyl- -1-propyπyl-amine in a therapeutically effective amount and optionally one or more neuroleptica and pharmaceutical¬ ly acceptable carriers, and other excipients. 2. A composition as claimed in claim 1 c o mp r i s i n g selegiline and optionally one or more neuroleptica in the form of capsules, tablets, retard tablets, injection, solution or syrup. 3. A composition as claimed in claim 1, c o n t a i n i n g as πeurolepticum chlorpromaziπe , thioridazine, flufenazine, haloperidol or pimozide. 4. A method of treatment of schisophrenia characterized .by negative symptoms, which c omp r i s e s applying an acid addition salt of (-)-N-(l-phenyl-iso- propyl)-N-methyl-propynyl-amine in an effective amount and during a sufficient time to stop or alleviate the symptoms of schisophrenia. 5. Process according to claim 4, which c omp r i s e s using selegiline as an acid addition salt . 6. Process as claimed in claims 4. and 5, which c omp r i s e s using daily 10 - -50 mg . of selegiline. 7. Process according to claims 4 to 6, which c omp r i s e s using 5 to 20 mg. of selegiline per dosage. 8. Process as claimed in claims 4 to 7, which c ompr i s e s carrying on with the treatment for at least one month.

Inventors: ARATO MIHALY, BELA ARPAD, FRECSKA EDE, KNOLL JOZSEF, PERENYI ANDRAS, UTPAL GOSWAMI, ARATO, MIHALY, BELA, ARPAD, FRECSKA, EDE, KNOLL, JOZSEF, PERENYI, ANDRAS, UTPAL, GOSWAMI
Applicants: CHINOIN GYOGYSZER ES VEGYESZET, CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT.
Application year: 1989
Main classification: A61K31
IPC codes: A61K31, A61P25